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Abstract: Cellular proteins that are hijacked by HIV in order to complete its replication cycle, form attractive new targets 
for antiretroviral therapy. In particular, the protein-protein interactions between these cellular proteins (cofactors) and 
viral proteins are of great interest to develop new therapies. Research efforts have led to the validation of different 
cofactors and some successes in therapeutic applications. Maraviroc, the first cofactor inhibitor approved for human 
medicinal use, provided a proof of concept. Furthermore, compounds developed as Integrase-LEDGF/p75 interaction 
inhibitors (LEDGINs) have advanced to early clinical trials. Other compounds targeting cofactors and cofactor-viral 
protein interactions are currently under development. Likewise, interactions between cellular restriction factors and their 
counteracting HIV protein might serve as interesting targets in order to impair HIV replication. In this respect, compounds 
targeting the Vif-APOBEC3G interaction have been described. In this review, we focus on compounds targeting the 
Integrase-LEDGF/p75 interaction, the Tat-P-TEFb interaction and the Vif-APOBEC3G interaction. Additionally we give 
an overview of currently discovered compounds presumably targeting cellular cofactor-HIV protein interactions. 
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1. INTRODUCTION 
With a cure or vaccination against HIV infection still out of 
reach, continued research on new antiviral therapies is 
warranted. Although existing combined anti-retroviral 
therapy (cART) is effective in controlling viremia, the 
occurrence of HIV drug resistance (HIVDR) remains a 
challenge 1. The high mutation rate resulting in extensive 
genetic diversity and the escape from cART in latently 
infected cells, along with poor patient compliance, all 
contribute to the emergence of resistant strains and treatment 
failure. With the purpose of preventing cross resistance 
between drug classes, it is essential to identify new 
therapeutic targets. Like all other viruses, HIV obligatory 
relies on cellular pathways and proteins (here referred to as 
cofactors) to complete its replication cycle. On the other 
hand, cells defend themselves against infection by use of so-
called restriction factors. During the last decade the scientific 
community has realized that virus-host interactions 
constitute a valuable alternative source of antiviral targets. 
Systematic validation of assumed cofactors as druggable 
targets is crucial in this process (reviewed in 2). This new 
line of research led to the development of a variety of new 
compounds currently in various stages of drug development 
and the FDA/EMA approval of the first cofactor inhibitor, 
maraviroc (Selzentry© in the US, Celsentry© outside US, 
ViiV Healthcare) 3. This compound 
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blocks HIV-entry upon binding to the human C-C 
chemokine type 5 receptor (CCR5), one of the HIV co-
receptors. Other compound classes are currently in clinical 
trials or in earlier development. An overview is given in 
table 1.  
Impairing HIV replication through inhibition of viral-host 
interactions could benefit from a reduced risk of antiviral 
resistance. Indeed, cellular proteins are less prone to 
evolutional adaptations, giving the virus theoretically less 
opportunities for resistance development. Inhibitors could 
potentially be developed to interfere specifically with the 
function of the cellular protein itself. For example, 
compounds inhibiting the DDX3 ATPase activity cause a 
block in HIV replication at non-toxic concentrations (table 
1)4. DDX3, necessary for viral RNA (vRNA) export, is a 
binding partner of the viral Rev protein. Alternatively, 
kinase-activity can be inhibited: either from kinases directly 
interacting with HIV proteins, or from kinases playing a role 
in pathways important for HIV disease progression. Targets 
include the kinase activity of CDK9 and HCK, which 
respectively interact with HIV Tat and Nef (illustrated in 
table 1) 5. However, this strategy is quite challenging, as 
most kinase inhibitors lack specificity and affect downstream 
processes, leading to toxicity. 
An alternative strategy could be to target specifically the 
protein-protein interaction between a cofactor and its 
interacting viral protein. For example, maraviroc and 
tirofiban (Aggrastat©, Eumedica) are FDA approved drugs 
targeting protein-protein interactions 3.
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Table 1. Overview of compounds targeting interactions between HIV proteins and cellular cofactors. 
 
Event 
 
Viral 
protein 
Cellular 
cofactor 
Mechanism Compound classes and 
examples 
Development stage Reference/company 
Entry  GP-120 CCR5 Binding to CCR5 CCR5 antagonists: 
Maraviroc (UK-427857) 
(Selzentry©/Celsentry©) 
 
Approved for human 
medicinal use 3 
 
 
Viiv-healthcare (Pfizer) 
PF-232798 Phase II6 
Aplaviroc (GSK-
873140/AK602) 
Stopped at phase III 7 Viiv-healthcare (Glaxo-Smith 
Kline) 
 
GSK-706769 Phase I 7 
Vicriviroc (SCH-417690) Stopped at phase III 7 Schering-Plough (Merck) 
SCH-532706 Phase I 8 
INCB009471  Stopped at phase II 7 Incyte Corporation 
Cenicriviroc (TBR652) Phase II 7 Tobira Therapeutics, Inc. 
NK1-receptor antagonist, 
leads to decreased CCR5-
expression 
Aprepitant (Emend©) Approved as anti-emetic 
In Phase 1 
Merck 
GP-120 CXCR4 Binding to CXCR4  
(allosteric modulator) 
CXCR4 antagonists: 
AMD070, AMD3100 1 
GSK812397 
 
Stopped phase I/II 7 
Preclinical 9 
 
AnorMed 10 
Viiv-healthcare (Glaxo-Smith 
Kline) 
GP-120 CD4  Binding to GP-120 and 
induction of 
conformational changes 
Attachment inhibitors: 
BMS-663068 (fostemsavir) 
BMS-378806  
NBD-556 and NBD-557 
 
Phase III 11 
Stopped at phaseI 
Drug Discovery 
Reviewed in.12 
CD-4 downregulation Cyclotriazadisulfonamide 
(CADA) and analogues 
Pre-clinical 
Uncoating and 
assembly 
Capsid Cyclophilin A Dual binding Thiourea derivatives: 
 K17, K24, K25 
Drug Discovery Li et al. 2009 13 
Chen et al. 2010 14 
Binding to Capsid interface 
on Cyclophilin A 
Methoxyphenyltriazolecarbox
amide based  compounds  
Drug Discovery Tian et al. 2013 15 
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Inhibition of Cyclophylin 
A activity2 
Peptidylprolyl isomerase A 
inhibitors: 
FD5, FD8-10, FD12 
Drug discovery  
 
Chen et al. 2007 16 
Reverse 
transcription 
Vif APOBEC3G Vif 
destabilization/downregula
tion 
RN-18 Drug discovery Nathans et al. 2008 17 
A3G stabilization  IMB-26, IMB-28 Drug Discovery Cen et al. 2010 18 
Binding likely to 
APOBEC3G 
N.41 Drug Discovery Pery et al. 2015 19 
Integration and 
maturation 
Integrase LEDGF/p75 Binding to the LEDGF/p75 
pocket on Integrase 
LEDGINs, ALLINIs, 
NCINIs:  
BI224436 
 
Phase I 
Patents reviewed in 20 
Vpr nuclear 
import 
Vpr Importin-α Binding likely to Vpr Hematoxylin Drug Discovery  Suzuki et al. 2009 21 
LTR-
transactivation 
Vpr Glucocorticoid 
receptor (GR) 
GR-antagonist Mifepristone Phase I/II 22 Schafer et al. 2006 23 
Refaeli et al.199524 
Transcription Tat P-TEFb CDK9 kinase inhibitors ATP site antagonists: 
Flavopiridol and analogues2 
Roscovitine and analogues2 
Indirubin 3′-Monoxime 
2-phenylquinazolinone 
fragments 
Drug discovery 
Anti-cancer compound   
Anti-cancer compound   
 
Chao et al. 2000 25 
Wang et al. 2001 26 
Heredia et al. 2005, 2013 27 
Sancineto et al. 2013 28 
Binding to CDK9 
interaction interface with 
Tat 
5-Ar-3-oxymethyl-Ar-1,2-
oxazole compound 
Drug discovery Van Duyne et al. 29 
Binding to Cyclin-T1 
interaction interface with 
Tat 
Benzothiadiazole-
sulfonamides: 
C1, C2, C3 
Drug discovery Hamasaki et al. 2012 30 
Nuclear export Rev EIF5α Inhibition of 
deoxyhypusine synthesis 
resulting in low ElF-5A 
activation2 
S-adenosylmethionine 
decarboxylase-inhibitors 
SAM486A (sardomozide) 
Drug discovery 
Anti-cancer compound 
Schäfer et al. 2006 31 
 
 
Deoxyhypusine synthase 
inhibitors: 
CNI-1493 (semapimod) 
Drug discovery 
Anti-inflammatory 
compound 
Hauber et al. 2005 32  
Crm1 Binding to Crm1 and 
disruption of Crm1-Rev 
PKF050-6383 
Ratjadone A4 
Drug discovery Daelemans et al. 2002 33 
Fleta-Sorjano et al. 2014 34 
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interaction Valtrate Murakami et al. 2002 35 
Crm1-DDX3 Inhibition of DDX3 
ATPase activity2 
ATP site antagonists 
Ring expanded nucleoside 
analogues 
Rhodanine derivatives 
Drug discovery  
Yedavalli et al. 2008 36 
 
Maga et al. 2008, 2011 4, 37 
Binding to DDX3 RNA 
binding site 
N,N’-diarylureas Drug discovery Radi et al. 2012 38 
Promotion of 
HIV 
pathogenesis: 
MHC-1 down-
regulation 
Nef HCK Binding to HCK-SR3 
binding pocket on Nef 
D14, DLC27 and analogues 
DQBS (diaminoquinoxaline 
benzenesulfonamide) 
Drug discovery Betzi et al. 2007 
39 
Trible et al. 2013 40 
Reviewed in 41 
Binding to Nef   
allosteric 
2c ( = 2,4-dihydroxy-5-(1-
methoxy-2-
methylpropyl)benzene-1,3-
dialdehyde) 
Drug discovery Dikeakos et al. 2010 42 
Disruption of Nef 
dimerization 
Diphenylpyrazolodiazenes: 
B9 
 
Drug discovery Emert-Sedlak et al. 2013 43 
 
Binding likely to the Hck 
active site 
Diphenylfuropyrimidines: 
DFP4A 
Drug discovery Emert-Sedlak et al. 2009 44 
Promotion of 
HIV 
pathogenesis 
including CD4 
down-
regulation 
Nef p56lck, p53, 
Actin 
Binding to Nef N-terminus Guanidine alkaloid analogs4 
 
Drug discovery Olszewski et al. 2004 45 
1 Long term toxicity in vivo 
2 (Expected to) have off target effects or downstream toxic effects 
3 Not tested on HIV-replication 
4Toxic  
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Tirofiban is an anti-aggregans indicated for the treatment of 
acute coronary angioplasty and instable angina. It inhibits 
blood platelet aggregation by blocking the interaction 
between glycoprotein IIb/IIIa receptors on platelets and 
fibrinogen and other ligands. However, targeting protein-
protein interfaces could be quite challenging, as they contain 
often flat, weakly defined and hydrophobic surfaces 46. 
Cofactor interaction inhibitors can either target the viral 
protein or the cellular factor. In the first case, resistance 
mutations, inhibiting the interaction with the small molecule, 
should not hamper the interaction with the cellular protein. 
Alternatively, resistant viruses could develop mechanisms to 
replicate independently from the cofactor or evolve to use 
alternative cofactors (recently reviewed in 47). In the second 
case the virus will escape a viral cofactor bound by a small 
molecule. Ideally, a druggable cofactor is crucial for HIV 
replication, but not for cell survival, as for example CCR5. 
Indeed, humans with a 32 basepair deletion in the ccr5 gene, 
which leads to the absence of the receptor on the cell surface, 
are healthy and naturally resistant to HIV infection 48. 
In this review we will focus on the development of different 
drug classes targeting interactions of HIV proteins with 
human cofactors. As another review in this journal discusses 
entry-inhibitors in detail, we focus on compounds inhibiting 
other important cofactor-HIV protein interactions, namely 
inhibitors of Integrase-LEDGF/p75, Tat-P-TEFb and Vif-
APOBEC3G. 
 
2. AN INTRODUCTION TO COFACTORS AND 
RESTRICTION FACTORS OF HIV REPLICATION 
The HIV genome (10 kb) encodes the Gag, Pol, Env 
proteins, the regulatory proteins, Tat and Rev and the 
accessory proteins, Vif, Vpr, Vpu and Nef. After protease 
cleavage, the Gag protein is cleaved into Matrix, Capsid 
(CA), Nucleocapsid, Spacer peptides 1 and 2, and p6, the Pol 
polyprotein into Reverse transcriptase (RT), Integrase (IN) 
and Protease, the Env into gp120 and gp41. In order to 
regulate and complete HIV replication, most, if not all, viral 
proteins interact with cellular proteins (cofactors).  
 
Efforts identifying these cellular proteins included genome 
wide siRNA screens 49, yeast two-hybrid screens 50 and large 
scale co-immunoprecipitation experiments followed by the 
identification of cellular interaction partners through mass 
spectrometry 51. Further virological and biochemical 
validation of these hits led to the discovery of cofactors 
involved in different steps of HIV replication, as shown in 
Figure 1. Out of the plethora of identified cofactors we 
focus on those cofactors explored for drug development. 
 HIV entry (Figure 1A): Interactions of the CD4 receptor 
and the CCR5 or CXCR4 co-receptors with viral gp120 
are essential for HIV attachment and entry and are 
currently a target of several drugs 52. 
 Reverse transcription (Figure 1B): CDK2 was 
demonstrated to support HIV RT activity in CD4 
positive T-cells, through phosphorylation of RT 53. This 
phosphorylation leads to an increase in activity and a 
stabilization of RT. 
 HIV uncoating and nuclear import of the pre-integration 
complex (Figure 1B, 1C):  Cyclophylin A (CypA) has 
been described to interact with the viral CA and to play 
a role in capsid stability facilitating viral replication 54. 
Also CPSF6 (cleavage and polyadenylation specific 
factor 6) and a non-physiologic truncation mutant 
(CPSF6 -358) have been described to interact with the 
CA protein 55. The function of this interaction is 
however still a matter of debate. In addition, the 
Importin-β-like protein Transportin-SR2 (TNPO3) and 
RANBP2 (RAN binding protein 2), also known as 
Nucleoporin 358 (Nup358), have been implicated in the 
import of the pre-Integration Complex (PIC) into the 
nucleus 56. 
 Integration (Figure 1D): LEDGF/p75, an IN interaction 
partner, is responsible for tethering the PIC to the host 
chromatin and thereby targeting integration into the 
body of active genes. The interaction with LEDGF/p75 
has been shown to be essential for HIV replication 
(reviewed in 2b).  
 HIV transcription and vRNA export (Figure 1E). The 
Positive Transcription Elongation Factor P-TEFb 
complex interacts with HIV Tat in order to activate 
RNA Polymerase II and promote elongation of viral 
transcripts 5a. The importin-β CRM1 and the Dead box 
helicase DDX3 interact with the Rev protein in order to 
export unspliced RNA transcripts 57. Also proteins 
interacting with the viral LTR and DNA/RNA have been 
described and can be considered cofactors. 
 Budding and viral assembly (Figure 1F): TSG101, an 
ESCRT I component, was found to interact with Gag-p6 
and to be essential for HIV budding 58. Also for ALIX 
(or Programmed cell death 6-interacting protein, 
PDC6I), binding to p6 and components in the ESCRT 
III pathway, a role in the budding process was 
elucidated 59.  
For the accessory protein Nef, different binding partners 
have been described as well, amongst them the Tyrosine 
protein kinase HCK (table 1) 5b. Binding of Nef to HCK 
triggers down-regulation of cell-surface MHC-I. 
Furthermore, different host-encoded restriction factors have 
been described, including APOBEC3G (A3G) and Tetherin 
(BST2). Restriction factors can serve as efficient inhibitors 
of viral replication, but are often counteracted by HIV 
accessory proteins. For instance, APOBEC3F/G (A3F/G), 
exerts innate antiretroviral immune activity by interfering 
with retroviral replication; however, HIV can counteract its 
effect by the Vif accessory protein 60. Therefore inhibition of 
this interaction should in theory hamper viral replication. 
Tetherin – another restriction factor and part of the IFN-
dependent antiviral response pathway - interferes with the 
release of virions by preventing the release of virus particles 
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from infected cells (Figure 2G). The presence of Tetherin in 
the plasma membrane is down-regulated through its 
interaction with Vpu. 
 
3. TARGETING THE INTEGRASE-LEDGF/p75 
INTERACTION 
The interaction of LEDGF/p75 with HIV IN is essential for 
HIV integration and as such for HIV replication 61. As 
compounds inhibiting integration by targeting IN catalytic 
activity, have been a clinical success, developing compounds 
interfering with the binding of LEDGF/p75 to IN, provide a 
valuable complementary strategy 3. 
3.1. Integration of the viral DNA into the host cell 
chromatin 
The viral IN catalyses the insertion of viral DNA (vDNA) 
into the host genome through 2 distinct reactions: 1) During 
the 3’ processing reaction in the cytoplasm, a dinucleotide at 
both 3’ ends of the vDNA is removed revealing the invariant 
CAOH-3’ ends. 2). Upon transport of the PIC to the nucleus, 
Figure 1, HIV replication cycle. A. The virus enters the cell through interaction with the CD4 receptor and the CCR5 or 
CXCR4 co-receptor. B. After entry, partial uncoating, reverse transcription of the viral RNA (vRNA) into double stranded 
DNA (vDNA) takes place. C. A pre-integration complex (PIC) is formed and transported into the nucleus. D. The PIC 
binds to LEDGF/p75 and is targeted to the host chromatin. Integration of the vDNA into the host chromatin is catalysed by 
the viral Integrase (IN).  E. After integration, the vDNA is silenced or transcribed into vRNA. Accessory proteins, 
including Tat, are expressed. Tat will recruit P-TEFb leading to elongation of viral transcripts. Spliced vRNA’s are 
exported to the cytoplasm and translated into the Gag and Gag-Pol precursor proteins. Unspliced full length vRNA binds 
through its Rev Responsive Element to Rev, which interacts with Crm1 and DDX3 in order to be exported. F. The viral 
precursor proteins Gag and Gag-Pol and the vRNA bud at the plasma membrane, a process mediated by TSG101. New 
virions are released through the ESCRT I and III pathways. G. The precursor proteins are cleaved by the viral protease and 
mature virions are formed. 
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the strand transfer reaction takes place. During this reaction 
the recessed vDNA ends are inserted 4-6 base pairs apart 
into opposing strands of the cellular DNA (recently reviewed 
in 62). The single-stranded gaps in the resulting DNA 
recombination intermediate are repaired by the host cell 
machinery. The viral IN consists of 3 domains: an N-
terminal domain (NTD), a catalytic core domain (CCD) and 
a C-terminal domain (CTD) (Figure 2) .The NTD has a 
HHCC zinc binding motif which stabilizes its 3 helix 
bundled structure. The CCD contains the DDE triad, which 
coordinates two magnesium ions responsible for its catalytic 
activity. The CTD forms a 5-stranded β-barrel. All three 
domains are involved in DNA binding and multimerization. 
In order to be functional, IN needs to form at least a dimer 
for the 3’processing reaction and a tetramer for the strand 
transfer reaction (recently reviewed in 62) 
Targeting the IN catalytic activity has shown to be a valuable 
approach, as illustrated by the approval of the inhibitors 
raltegravir (Isentress©), elvitegravir (in Stribild©) and 
dolutegravir (Tivicay©) 3. Those compounds inhibit the IN 
strand transfer reaction and therefore are referred to as 
INSTIs (Integrase Strand Transfer Inhibitors). Inhibition of 
integration results in a strong reduction in viral load.
 
3.2. The role of LEDGF/p75 during HIV replication 
After its initial discovery as an IN binding partner in 2003 63, 
LEDGF/p75 got thoroughly validated as an essential 
cofactor of HIV integration (reviewed in 2a and 2b). Briefly, 
mutagenesis, RNA interference, transdominant 
overexpression of the Integrase binding domain (IBD) of 
LEDGF/p75 and KO studies demonstrated the importance of 
LEDGF/p75 during viral replication. 
LEDGF/p75, a 530 amino acid nuclear protein, is a member 
of the Hepatoma Derived Growth Factor (HDGF) family. It 
is encoded by the PSIP1 gene, located on chromosome 
9p22.2, together with its smaller splice variant LEDGF/p52 
64. All HDGF proteins are characterised by an N-terminal 
PWWP-domain recognizing H3K36 tri-methylated 
chromatin 65. Next to this, LEDGF/p75 and its splice variant 
share a nuclear localisation signal (NLS), two DNA binding 
AT-hooks and charged regions forming a supercoiled-DNA 
recognition domain (SRD) 66. The p75 specific C-terminal 
tail is characterised by the presence of the IBD, known to 
interact with lentiviral integrases 66-67 and several other 
cellular proteins 68 (Figure 2). Due to the presence of the 
IBD and its histone and DNA binding properties, 
LEDGF/p75 is able to tether and target HIV into active 
chromatin 69. Next to its tethering function, LEDGF/p75 
stabilizes IN multimers, promotes IN catalytic activity in 
vitro and protects IN from proteosomal degradation 70. 
According to the crystal structure of the LEDGF/p75 IBD 
with the CCD of HIV-IN, the LEDGF/p75 IBD monomer, a 
compact right handled bundle of 5 alpha-helices, binds to a 
well-defined pocket formed by a dimer of IN CCDs (Figure 
3A, 3B) 71. The IBD recognizes residues 168-171 from the 
first monomer and a hydrophobic patch formed by the 
backbones of alpha-helices 1 and 3 of the second monomer 
(Figure 3B). The critical LEDGF/p75 residues are I365, 
D366 and F406. The relevance of this crystal structure was 
confirmed by mutagenesis studies 72. 
3.3. Targeting the LEDGF/p75 Integrase interaction 
While knockdown, knockout and mutational analysis 
revealed that LEDGF/p75 is crucial for viral replication, 
overexpression of the IBD or LEDGF/p75 based peptides 
validated the LEDGF/p75-IN interaction as a druggable 
target 73. Overexpression of the IBD outcompetes 
endogenous LEDGF/p75 from the PIC, blocking interaction 
of the PIC with the chromatin and thereby viral replication 
72a, 73a. Cyclic peptides directly binding to LEDGF/p75
Figure 2, LEDGF/p75 and Integrase domains. A schematic representation of HIV Integrase and LEDGF/p75. HIV 
Integrase contains an N-terminal domain (NTD), a catalytic core domain (CCD) and a C-terminal domain (CTD). 
LEDGF/p75 contains N-terminally a PWWP-domain (PWWP), a nuclear localisation signal (NLS), two AT-hook motifs 
(AT) and a supercoiled recognition domain (SRD). C-terminally it contains the Integrase binding domain (IBD) responsible 
for protein and integrase binding. The D366 residue responsible for integrase binding is marked by a star.  
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Figure 3, LEDGINs bind 
to the LEDGF/p75 binding 
pocket on HIV-1 IN. 
Structures are shown of the 
LEDGF/p75 IBD or C3 in 
complex with HIV-1 
Integrase (IN), based on 
pymol ID 2B4J and 3LPI. 
A. The LEDGF/p75 
Integrase binding domain 
(IBD) (black) binds into a 
pocket formed by two 
Integrase catalytic domains 
(CCD1 in white and CCD2 
in grey).  B. Detail of 
LEDGF/p75 IBD binding to 
the CCD dimerization 
interface. LEDGF/p75 
residue I365 sits in a 
hydrophobic pocket, which 
contains W132 and A128, 
and makes a hydrogen bond 
with the backbone amide of 
CCD1 residue Q168. 
LEDGF/p75 residues F406 
and V408 interact with 
W131 in CCD2. The 
LEDGF/p75 key residue for 
IN binding, D366, makes a 
double hydrogen bond with 
the main-chain amides of 
E170 and H171 of CCD1. 
Furthermore, the CCD1 
E170 also makes a salt 
bridge with LEDGF/p75 
K364. C., D. C3 binds into 
the IN LEDGF/p75 binding 
pocket and is able to 
displace LEDGF/p75. The 
consensus pharmacophore 
of LEDGIN development 
was based on LEDGF/p75 
residues I365, D366 and 
L368 74. Figures were 
adapted with PyMOL 
software 75. 
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were able to inhibit LEDGF/p75 binding to Integrase and as 
a consequence HIV replication 76.Peptides developed by Al-
Mawsawi et al. modestly inhibited IN catalysis in vitro; this 
inhibition was dependent on IN-DNA assembly 73c. These 
data together with the IBD-CCD co-crystal structure (PDB 
ID 2BJ) and a structure of the CCD with the LEDGF/p75 
binding pocket occupied by tetraphenylarsonium (PDB ID 
1HYV), enabled the rational design of small molecules 
binding the IN CCD dimer interface inhibiting the 
LEDGF/p75 interaction 71, 74, 77. Apart from structure based 
design, different other approaches were used to develop 
compounds targeting the LEDGF/p75 – IN interaction, 
including high throughput screening (reviewed in 2b). By 
now, most pharmaceutical companies with a HIV program 
are involved in the development of these inhibitors (patents 
reviewed in 20). 
The structure based approach led to the discovery of 2-
(quinolin-3-yl)acetic acids as the first in class compounds 
targeting the LEDGF/p75 binding pocket on HIV IN 74 
(Figure 4, table 2). Fitting of a 200 000 compound library 
against a consensus pharmacophore model (Figure 3B) and 
evaluation of the best hits in a LEDGF/p75-IN AlphaScreen 
interaction assay, led to the discovery of C1 (1). Validation 
and optimization by medicinal chemistry resulted in C3 (2) 
which inhibited HIVIIIB replication in MT-4 cells with an 
EC50 of 41.9 ± 1.1 µM and the LEDGF/p75-IN interaction 
with an IC50 of 12.2 ± 3.4 µM 74. Co-crystallization of this 
compound (2) (Figure 3 C), and subsequent optimization 
resulted in the more potent inhibitors CX05168 (3), 
CX05045 (4) and CX014442 (5) 78, inhibiting HIV 
replication in the nanomolar range (table 2). Of note, 
CX014442 showed an EC50 of 69±3 nM and a selectivity 
index (SI) of 1391, similar to that of FDA approved HIV-
drugs. The inhibitors were found to inhibit Integrase 
allosterically during 3’ processing and strand transfer when 
the compound and IN were pre-incubated before the addition 
of LTR - or target DNA. Of note, similar compounds with an 
indole scaffold which are able to interrupt the LEDGF/p75-
IN interaction in vitro were described by De Luca et al. in 
2009 and optimized later on 79. 
In an independent approach, Boehringer-Ingelheim (BI) 
identified similar compounds, Tert-butoxy-(4-phenyl-
quinolin-3yl)-acetic acids (Figure 4, table 2), inhibiting the 
3’ processing reaction (NCINI or non-catalytic site Integrase 
inhibitors) (6, 7, 8)) 80. Medicinal chemistry in combination 
with rational design, led to the discovery of BI224436 (9), 
which inhibits the 3’ processing reaction with an IC50 of 19 ± 
4 nM and also binds in the LEDGF/p75 binding pocket on 
the IN CCD 80b. This compound was tested for safety and 
pharmacokinetics in a phase I clinical trial, as it showed 
excellent antiviral activity and acceptable pharmacokinetic 
characteristics in vitro 7, 80a . The compound exhibited a low 
clearance due to enterohepatic recirculation of the parent- 
and acyl glucuronide metabolite. This observation prompted 
the researchers to optimize the compound through a scaffold 
replacement approach which resulted into a pyridine based 
compound (BI compound 20 (10)) with a reduced biliary 
excretion in rat 81. These compounds were also described by 
Sharma et al. as multimerization selective inhibitors of HIV 
Integrase 82. 
Many other compounds with similar biochemical and 
virological properties have since been disclosed 83 (reviewed 
in 20). Since all compounds bind to the LEDGF/p75 binding 
pocket of HIV-1 Integrase, we proposed the class name of 
LEDGINs. Other potential inhibitors of the LEDGF/p75 – 
IN interaction have been described such as atorvastatin (only 
tested in vitro), natural product derivates, acylhydrazones 
and diketo-acids 84, although no co-crystals are available for 
these inhibitors. 
3.4. Mechanism of inhibitors targeting the LEDGF/p75 
Integrase pocket. 
LEDGINs displace LEDGF/p75 from the IN pocket, and 
enhance IN multimerization. 74, 78, 83a, 83c, 85. They show 
activity against a broad spectrum of HIV clades (HIV IIIB, 
HIVBAL, HIVU2, HIVNL4.3, HIVHXBD2) and clinical isolates, but 
not against HIV-2 and SIV, due to a different amino acid at 
position IN 128, which interacts with I365 included in the 
pharmacophore 74, 80b. The resistance mutation IN A128T is 
responsible for an 8.65- to 11-fold change of the EC50 of 
CX05045 (4) and CX014442 (5), respectively while A128N 
and L102F induce a 64-and 60-fold change of the EC50 of 
BI224436 (9). Other single resistance mutations identified 
are the Y99H, Y99N A129T and H171T 78, 86. Although 
LEDGINs block early replication at the integration step, no 
resistance to INSTIs was observed with LEDGIN-resistant 
viruses. Furthermore, LEDGINs act additively or slightly 
synergistically with INSTIs, and with most NRTIs, NNRTIs, 
PIs and entry inhibitors (78, 80b). LEDGINs display steep 
dose-response curves, resulting in EC95 values only ~2.4-fold 
higher than the EC50 values 74, 80b, 85b, c. Such steep Hill slopes 
are of importance as they indicate that at clinically relevant 
compound concentrations, these inhibitors can have a more 
pronounced effect on viral suppression 80b. LEDGINs affect 
3’ processing and strand transfer in vitro. CX014442 (5) 
could inhibit the IN strand transfer reaction with an IC50 of 
146 nM when incubated with HIV-IN prior to addition of the 
HIV LTR 78. 3’ processing was inhibited to a same extent. 
Also BI-1001 (7) impaired strand transfer and 3’ processing 
with similar potency (IC50= 1.7 and IC50=2.3 respectively) 
85c. Integration inhibition in vitro can be explained by 
enhanced IN multimerization 78, 85c. In vivo, LEDGINs 
exhibit an enhanced potency in LEDGF/p75 knock-out cells, 
pointing out the necessity of displacing LEDGF/p75 during 
the early stage of HIV replication 61d. In conclusion, 
inhibition of integration is due to the displacement of 
LEDGF/p75 and to a LEDGIN-induced increase in the 
stability of the IN multimer; both mechanisms cannot be 
uncoupled in the infected cell 2b. 
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Figure 4, LEDGINS and analogues. Shown are the compounds developed by KU Leuven (1-5) and BI (6-10).  
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Table 2, Antiviral activity of the displayed compounds 
Target Compound # Compound name EC50 (µM) EC50 measurement 
LEDGF/p75 binding 
pocket on HIV-
Integrase 
1 C1 / Not determined in 
cellulo 
2 C3 41.9±1.1 HIVIIIB in a MT4 -MTT 
assay 74, 78 3 CX05168 2.35 ± 0.28 
4 CX05045 0.76 ± 0.08 
5 CX014442 0.069 ± 0.003 
6 BI A > 40 HIV HXB2 in C8166 
LTRIuc cells80a 
 
7 BI-1001 0.99 
8 BI-D 0.051 ± 0.031 HIVNL4.3 in C8166 
LTRIuc cells 81 
9 BI224436 0.0072 - 0.015 HIVHXB2, HIVNL4.3 or 
HIVBal on PBMCs 80b, 81 10 BI224436 derived  
compound 20 
0.0065 - 0.810 
ATP site of CDK9 11 Flavoperidol 0.006-0.0125 NL4.3 in Jurkats 25 
12 Roscovitine 0.36 Upon TNFα/PMA 
stimulation of OM10.1s 
5 days post infection28, 87 
13 Compound 37 4.0 
14 CR8#13 <0.010 
15 Compound 93 0.142 HIVIIIB in MT-4s 88 
16 Indirubin-3’-monoxim 0.5-2  HIVADA and HIVIIIB in 
PBMCs 27a 
Tat-CDK9 interface 
(CDK9) 
17 F07 ~0.6  In HLM-1 cells 
transfected with Tat 29 18 F07#13 0.12  
Tat-Cyclin-T1 interface 19 C1 4.2 Upon TNFα stimulation 
of OM10.1s 5 days post 
infection 30 
*HIVIIIB in PBMCs 
20 C2 4.8 
21 C3 0.617 ± 0.011 
0.0097* 
Vif/APOBEC3G 
stability 
22 RN-18 4.5-10* HIVLA-I in H9s 17-18 or * 
in CEM cells 17 23 RN-18 analogue 5d 5.9 
24 RN-18 analogue 40j 2.8 
25 RN-18 analogue 17 1 
APOBEC3G 
degradation 
26 IMB-26 0.017 
27 IMB-35 0.017 
Vif-ElonginC interface 28 VEC-5 24.48 NL4.3, produced in 
293T-cells expressing 
APOBEC3G, in MAGI-
CCR5s 89 
Vif-APOBEC3G 
interface 
29 N.41 8.4-22.6 or HIVBal on PBMCs 19 
a finished a clinical phase I trial 
 
LEDGINs also affect late stage HIV replication through 
stimulation of IN multimerization leading to defective viral 
particles displaying a nucleoprotein complex outside the 
capsid cone 83b, 85b, 90. These immature particles show a defect 
in RT activity and nuclear import during the next infection 
round. Moreover, LEDGINs were shown to interact with IN 
as a part of the Pol precursor and induce oligomerization 
[118]. 
Although potencies obtained in experiments conducted at 
various stages of HIV replication cannot be directly 
compared, LEDGINs tend to show a higher potency for 
impairment of the late stages of HIV replication compared to 
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the early stages 83a, b, 90. This finding implies that during the 
early phase of HIV replication LEDGINs have to compete 
with the endogenously present LEDGF/p75 and that potency 
will depend on the LEDGF/p75 levels in the infected cell. 
Compared to the cellular levels these levels will be much 
lower in viral particles during the late stages of 
infection91. This idea is corroborated by the fact that the 
potency of LEDGINs during early stages increases when 
LEDGF/p75 is depleted whereas the potency of LEDGINs 
during late stages is similar for viruses produced in wild type 
or LEDGF/p75-depleted cells 61d, 91-92. 
3.5. Conclusion 
In conclusion, LEDGINs form a promising class of 
compounds for further drug development. As LEDGINs can 
be combined with most clinically approved HIV drugs 78, 80b, 
they might become an integral part of cART in the future. 
 
4. TARGETING THE TAT-P-TEFb INTERACTION 
The HIV-1 Transactivator of transcription (Tat) is an 86-101 
amino acid protein (Figure 5A). It contains a conserved 
activation domain (AD) and a nuclear localisation signal 
(NLS) also responsible for RNA binding (Figure 5A). In 
absence of binding partners it has no pronounced secondary 
structure elements 93. Tat interacts with the transactivation 
responsive (TAR) RNA of HIV and the cellular positive 
transcription elongation factor (P-TEFb) complex in order to 
promote efficient elongation of HIV transcripts 5a, 94. As this 
complex is key for efficient HIV transcription, targeting the 
P-TEFb-Tat interaction might form an interesting therapeutic 
approach.  
4.1. P-TEFb promotes HIV transcriptional elongation 
Tat-mediated recruitment of the P-TEFb complex to the 
TAR region promotes viral transcription elongation through 
P-TEFb-dependent phosphorylation of S2 and S5 in the 
hepta-repeats of the C-terminal domain of RNA polymerase 
II 5a, 94-95. P-TEFb is a Cyclin-dependent kinase, which 
embodies Cyclin-dependent kinase 9 (CDK9) and a Cyclin, 
in case of HIV infection Cyclin-T1 (CycT1) 94a (structure 
reviewed in 96). Apart from recruiting P-TEFb to the vRNA, 
Tat also stimulates the P-TEFb kinase activity and changes 
its substrate specificity 97. Additionally, Tat is able to release 
P-TEFb from its regulator 7SK snRNP, keeping it in an 
inactive form through its interaction with HEXIM1 98. CDK9 
is a 372 amino-acid member of the cyclin-dependent kinase 
family, which are key cell cycle regulators. CDK9 encloses a 
kinase domain, including the T-loop which is able to bind 
Tat (Figure 5A). CDK9 forms a complex with Cyclin K or 
Cyclin T. Cyclin T is a member of the conserved cyclin C 
subfamily and exists in 3 different forms: CycT1, Cyclin-
T2a an Cyclin-T2b. CycT1, which can interact with Tat, is a 
726 amino acid protein which contains an N-terminal cyclin 
like domain (CLD) (Figure 5A).  
 
4.2. Tat-P-TEFb interaction 
Truncations and mutational analysis revealed that CycT1 is 
able to interact with TAR and Tat through a minimal binding 
domain, a region called the Tat/TAR recognition motif 
(TRM), which comprises amino acids 250-262 (Figure 5A) 
99. In particular N250, R259 and C261 were found to be 
crucial for Tat binding. The crystal structure of Tat 
complexed with P-TEFb (PDB ID 3MIA) 100 revealed that 
Tat binds to both the CDK9 and the CycT1 units (Figure 
5B). Tat binds to a groove at the heterodimer interface, 
which leads to a more stable and active P-TEFb complex 
(Figure 5B). The Tat acidic/proline-rich region forms an 
extended loop conformation, containing 2 type II β-turns and 
one type II’ β-turn (Figure 5A, 5B). The cysteine-rich and 
core regions contain a random coil, two helices, a tail and 
two bound zinc ions (Figure 5A, 5B). The second zinc ion is 
coordinated by 3 cysteines of Tat and one of CycT1, C261 
(Figure 5A, 5C). In addition, Tats AD contains a 
hydrophobic patch binding to the hydrophobic surface of 
CycT1. Furthermore Tat forms direct and water-mediated 
hydrogen bonds with CDK9 and CycT1, stabilizing its 
conformation. CDK9 interacts with Tat through its T-loop 
region (Figure 5A, Figure 5B). Upon binding with Tat, 
CDK9 undergoes conformational changes, explaining why 
Tat bound P-TEFb is able to not only phosphorylate S2 in 
the RNA Polymerase II CTD, but also S5.  
4.3. Targeting the P-TEFb-Tat interaction 
Until now, antiretroviral therapy does not contain 
compounds targeting HIV transactivation. Moreover, 
compounds interfering with the release of viral particles 
from HIV reservoirs are unavailable, which makes Tat-P-
TEFb an attractive target in order to reduce transactivation of 
HIV replication of already infected cells (also recently 
reviewed in 101). Furthermore, Tat seems to be the main 
determinant to control latency 102. Hence, compounds 
targeting Tat-P-TEFb could potentially impair 1.) 
reactivation from latently infected cells, 2.) 
expansion/replenishment of the latent reservoir. 3.) basal 
HIV replication in patients under current cART therapy, 
which is believed to play a role in co-morbidities (as also 
stated in 101). Reducing the latent reservoir could be an 
alternative strategy for the ‘purge and kill’ strategy put 
forward the last decade 103. Hereby the latent reservoir is 
reactivated in order to be targeted by cART and to be killed 
by the host immune system. HIV transactivation inhibitors 
provide a valuable alternative.  
In order to impair HIV transcription elongation, different 
strategies can be envisaged: One may target either 1.) CDK9 
kinase activity, 2.) Tat-CDK9 interaction, 3.)Tat- CycT1-
interaction, or 4) Tat itself and its interactions with TAR (not 
discussed in this review). Specific impairment of HIV 
transcription will be challenging, as by inhibiting P-TEFb 
also general cellular transcription processes might be 
affected. However, the observation that Tat induces 
conformational changes in CDK9 implies that the design of 
specific Tat-P-TEFb inhibitors can be undertaken 100.  
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Figure 5, The Tat-pTEFb complex. A. Schematic representation of Tat and PTEF-b. Tat comprises an activation domain 
(AD), consisting of an acidic/proline-rich region (1-20), a cysteine-rich/zinc finger (CHCC and CCC) containing region (20-
40), a core domain (40-48), and a nuclear localisation signal (NLS). The NLS domain is also responsible for RNA-binding. 
This region is followed by a glutamine-rich region (57-72). CDK9 contains a protein kinase domain, with the ATP binding site, 
a Serine/Threonine protein kinases active-site signature ([LIVMFYC]-x-[HY]-x-D-[LIVMFY]-K-x(2)-N-[LIVMFYCT]) and 
the activation loop (T-loop (TL)). Cyclin-T1 contains a Cyclin like domain (CLD), a nuclear localisation signal (NLS) and a 
PEST sequence, which is a signal for rapid cellular proteolysis. The Tat/TAR recognition motif is shown (TRM). The C261 
amino acid which interacts with Tat through a Zinc bridge is marked with a star. B. Structure of the Tat-P-TEFb complex. 
Amino acids 1-49 from Tat, corresponding to the Tat activation domain, are solved in this structure. Tat binds with its 
acidic/proline rich (A/P) region to the T-loop of CDK9. Also the ATP binding pocket (ABP) of CDK9 is shown. Tat binds in 
extended conformation to Cyclin-T1 (CycT1), through hydrophobic interactions and salt bridges. Tat contains 2 zinc fingers, 
the second one forms a zinc mediated bridge with CycT1 C261. C. Detail of zinc binding by Tat and CycT1. Figures B, C were 
based on PDB ID 3MIA and adapted with pymol software 75. 
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Knock-down studies, mutational analysis, use of a Tat, 
CDK9 and CycT1 dominant negative form, Tat fusion 
proteins and the availability of a crystal structure of the Tat –
P-TEFb complex and the EIAV Tat-TAR complex, validated 
the Tat-P-TEFb(-TAR) complex as a druggable target 99b, 100, 
104. Furthermore peptides and cellular proteins which are able 
to compete with Tat for -P-TEFb binding have been 
described 105. 
4.3.1 CDK9 kinase inhibitors 
Around the late ‘90s, the first kinase inhibitors targeting the 
Tat-P-TEFb complex were discovered 25-26, 106. Although 
more than a decade of research passed by, nowadays none of 
these inhibitors is enrolled in clinical trials for HIV treatment 
since specific inhibition of the kinase activity of CDK9 
without impairing the downstream cellular processes 
mediated by CDK9, has not been achieved so far. 
4.3.1.1 CDK9 kinase activity inhibitors or ATP site 
antagonists 
The most common strategy to impair the activity of a kinase 
is to block the ATP binding pocket with a small molecule. 
ATP site antagonists, including flavoperidol (11) and 
roscovitine (12), are able to block CDK9 kinase activity and 
as such, HIV replication 25-26 (Figure 6, table 2). 
Flavoperidol (11) inhibits general mRNA production and is 
therefore under clinical development for the treatment of 
chronic lymphocytic leukemia and solid tumors (alvocidib) 7. 
Roscovitine (12) (seliciclib) is also evaluated for treatment 
of different cancers and Cushing disease 7. Due to the high 
similarity of the ATP binding pockets, development of more 
specific CDK9 inhibitors remains a challenge. Although 
some efforts to develop less toxic and more specific 
flavoperidol analogues were undertaken, interference with 
general cellular processes remained an issue 107. Most 
progress in obtaining more specific CDK9 inhibitors has 
been achieved by a recent in silico study starting from 
flavoperidol in complex with P-TEFb, where a new class of 
non-toxic anti-CDK9 compounds based on the 2-
phenylquinazolinone scaffold was identified 28. The most 
potent compound of this study was compound 37 (13) (2-(4-
aminophenyl)-7-chloroquinazolin-4(3H)-one), which 
affected HIV transcription in OM-10.1 cells upon phorbol 
myristate acetate (PMA) stimulation with an EC50 of 4.0 µM 
and an SI of 86. OM-10.1 cells contain a single integrated 
provirus and show a minimal constitutive HIV-1 production. 
Upon TNF-α treatment, HIV transcription increases 30-1000 
fold 24-72 hours post treatment in these cell lines. Also 
analogues of roscovitine with enhanced safety profile have 
been described, for example CR8#13 (14), able to inhibit 
HIV replication in OM10.1 cells with an EC50 of less than 10 
nM 87b, 108.  
Other specific CDK9 kinase inhibitors have been reported, 
although they still show some off target effects and act on 
general transcription processes. For example, the phoshonic 
compound 93 (15) from Nemeth et al. interacts mainly with 
the CDK9-CycT1 complex, and not with free CDK9; 
however, it does not provide protection of MT-4 cells against 
HIV infection 88. Furthermore indirubin-3’-monoxim (16), 
derived from a Chinese anti-leukemia herbal medicine, is a 
CDK9 inhibitor which impairs HIV replication in PBMCs 
and macrophages at non-toxic concentrations 27a. Recently, 
evaluation in a humanized mouse model showed activity 
against a multidrug resistant HIV strain, but more extensive 
toxicological and pharmacokinetical evaluation is required 
27b.  
Overall, targeting the kinase activity of CDK9 using 
compounds targeting the CDK9 ATP pocket as a therapeutic 
strategy for HIV treatment is not yet feasible, as the balance 
between antiviral activity and cytotoxicity is a thin line due 
to non-specific binding to other kinases and the interference 
with cellular processes mediated by CDK9. To circumvent 
these problems future drug development could focus on Tat-
P-TEF-b kinase inhibitors, as binding of Tat changes the 
conformation of the CDK9 and so, the substrate specificity. 
4.3.2 Tat-CDK9 interaction inhibitors 
Another strategy aims at targeting the CDK9-CyclinT1 
interface which is occupied by Tat, in particular the Tat 
binding interface on CDK9. Tat based peptides targeting the 
pocket of the CDK-Cyclin complex, binding to CDK2 and 
CDK9, were used to obtain a pharmacophore model in order 
to select small-molecule ligands occupying the CDK-Cyclin 
interface 29. CDK2 is similar to CDK9 and the Tat-based 
peptides were found to bind both molecules. High-
throughput docking of compounds to the binding pocket of 
CDK9 and further evaluation in HIV-1 infected cells, led to 
the discovery of F07 (17), a 5-Ar-3-oxymethyl-Ar-1,2-
oxazole compound (Figure 6, table 2). Specificity of the 
inhibition of Tat transactivation was further evaluated using 
TZM-bl cells, containing a LTR-luciferase reporter gene, and 
HLM1, containing a Tat-defective provirus that can be 
complemented with a Tat expression construct. A next 
generation compound (F07#13) (18), a result from SAR 
optimization, showed activity against multiple HIV strains in 
PBMCs. Well known genes regulated by CDK9 showed no 
alteration in expression in HIV infected PBMCs. 
Furthermore, an in vivo evaluation of F07#13 (18) in a 
humanized mouse model demonstrated effective inhibition 
of HIV replication and no toxicity upon 3 months after initial 
treatment. Docking revealed that F07#13 (18) preferentially 
targeted the Tat interface pocket on CDK9 in presence of 
Tat. This result was in line with the observation that CDK9 
could only be dissociated from the HIV transcription 
complex in an in vitro assay when Tat was present.  
In conclusion, this compound has an inhibitory mechanism 
different from that of ATP analogues, and may dissociate 
CDK9 from Cyclin in vivo. Some additional evaluation for 
the specific binding to the CDK9-CycT1-Tat complex seems 
required, as the binding of other Cyclin dependent kinases 
was not evaluated. Furthermore, a crystal of the P-TEFb 
complex including the compound would be of great help for 
further optimization.
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Figure 6, Tat-P-TEFb inhibitors. Shown are compounds biding to the CDK9 ATP pocket (11-16) and compounds 
developed by Van Duyne et al. (17-18) and Hashamaki et al. (19-21). 
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4.3.3 Tat-Cyclin-T1 inhibitors 
Compounds targeting the TRM of CycT1 were described by 
Hamasakii et al. in 2012 30 (Figure 6, table 2). A large 
compound database was screened in silico against a model of 
the CycT1 TRM based on the crystal structures of the EIAV 
Tat/TAR RNA complex (PDB ID 2W2H) and the human 
CDK9/CycT1/HIV-1 Tat complex (PDB ID 3MIA, 
described above). Compounds C1 (19) and C2 (20) inhibited 
HIV-1 replication in chronically infected OM-10.1 cells, 
upon TNF-α stimulation, with an EC50 of 4.2 and 4.8 µM, 
respectively. A C1 and C2 derivate, C3 (21), was able to 
impede HIV-1 replication with an EC50 of 617 ± 11 nM in 
OM-10.1 cells. Additionally, HIVIIIB replication in CEM, 
MOLT-4 and PBMCs was inhibited by C3 (21) with a 
potency of respectively 19.9 ± 3.4 nM, 17.9 ± 6.6 nM and 
9.6 nM. Moreover, the compound seemed well tolerated in 
PBMCs with an SI of 708. In conclusion, these compounds 
seem promising for further development, and form a proof of 
concept for Tat-CycT1 inhibitors. However, the difference 
between EC50’s in OM-10.1 and PBMCs could point towards 
an additional inhibitory effect, and so, further research is 
necessary. 
4.3.3 Conclusion 
Compounds inhibiting the Tat-P-TEFb complex could be a 
valuable addition to cART. In particular the fact that no HIV 
transcription activation inhibitors are available yet, makes 
the Tat-P-TEFb complex a target of great interest. ATP site 
antagonists targeting the CDK9 ATP pocket might not be the 
best option for now, as even compounds which would be 
completely selective for CDK9, could still interfere with 
downstream processes. Therefore the focus should be on 
specific inhibitors of the complex, targeting interactions 
between Tat, CDK9 and CycT1 or targeting the CDK9  
pocket when CDK9 is in complex with Tat and CycT1. 
 
5. TARGETING THE Vif-APOBEC3G INTERACTION 
A3G-mediated restriction of retroviral replication is 
efficiently counteracted by HIV-1 Vif 60. It follows that 
inhibition of the Vif-A3G interaction can be considered an 
interesting potential antiviral target. 
5.1. HIV-1 Vif, the Virus infectivity factor. 
The 23 kDA Virus infectivity factor (Vif) resides mainly in 
the cytoplasm and is expressed from partially spliced mRNA 
in a Rev-dependent way 109. Vif contains an N-terminal 
region which is responsible for RNA and A3F/G binding, a 
central HCCH zinc binding motif responsible for Cul5 
interaction and a C-terminal region with a BC-like box, 
responsible for EloC binding and a multimerization domain 
(Figure 7) (reviewed in 110). It is essential for HIV 
replication in primary lymphoid and myeloid cells, but not in 
several transformed T-cell lines, nor in non-lymphoid cell 
lines such as HeLa and HEK293T cells. It inhibits 
encapsidation of A3F/G through targeting it for proteosomal 
degradation after recruiting an E3 ubiquitin ligase complex, 
which consists of Cullin5 (Cul5), ElonginB (EloB), Elongin 
C (EloC), CBFβ and RING-box protein 2 (RBX2) 111. Cul5, 
EloB, EloC, CBFβ and nearly full length Vif have been co-
crystallized in 2014, which could lead to more insights 
concerning the interaction between Vif and this complex. Vif 
also interferes with the A3F/G antiviral activity through 
interfering with its packaging and expression through 
different pathways 112. Furthermore Vif possesses RNA 
binding and chaperone properties 113. Transdominant Vif 
mutants have been described, which open the door for 
strategies targeting Vif 114.
 
Figure 7, Vif and ABOPBEC3G domainsA schematic representation of the Vif and APOBEC3G domains is shown. The 
Vif N-terminus interacts with APOBEC3F, APOBEC3G and RNA. Vif contains a Zinc binding motif (HCCH) responsible 
for Cullin5 binding, a BC-box-like motif (BC) binding to ElonginC and a multimerization domain (MD). APOBEC3G 
contains 2 cytidine deaminase zinc binding domains (CCD), of which only the first one is catalytically active. The D128 
amino acid responsible for Vif binding is marked by a star. 
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5.2. APOBEC3G inhibits HIV replication through 
enhancing innate immunity 
In 2002 Sheehy et al. discovered that APOBEC3G inhibits 
HIV replication when Vif is not present 60. Since then, 
different groups unravelled its role in HIV replication 
(reviewed in 110). A3G, a 384 amino-acid protein, is the most 
widely studied enzyme of the Apolipoprotein B mRNA-
editing enzyme catalytic polypeptide-like 3 family 
(APOBEC3 (A3)), a family of polynucleotide cytidine 
deaminases (reviewed in 115). The protein plays a role in 
innate immunity by restricting viruses with ssDNA 
intermediates. Although A3G is counteracted by Vif, 
patients with high levels of A3G are less likely to become 
infected with HIV or to progress to AIDS 116.  
A3G mainly, but not solely, acts through its deoxycytinidine 
deamination activity which results in hypermutated and 
inactivated viral genomes (recently reviewed by 110). In the 
absence of Vif, it is incorporated into viral particles through 
its interaction with the vRNA. Post entry, A3G deaminates 
deoxycitidines leading to deoxyuridines in the ss (-) DNA 
during reverse transcription 117. Also other A3 proteins play 
a role in hypermutating vRNA, especially A3F has been 
validated as a restriction factor for HIV replication (reviewed 
in 110). A3G contains two Zinc coordinating catalytic 
domains, of which one is catalytically active and a linker 
region containing residues responsible for its RNA-
interaction, encapsidation and oligomerization (Figure 7).  
5.3. The Vif -APOBEC3G interaction 
Different efforts have been undertaken to unravel the 
interaction between Vif and A3G (reviewed in 110). The Vif 
Y69 and L72 amino-acids are found critical for A3G-
binding, the DPD-motif (residues 128-130) on A3G for Vif 
binding. A D128K mutation in A3G renders the protein 
resistant for Vif binding. A recent overview of A3 
interacting motifs is given in 118. Because no structural data 
from a co-crystal of Vif and A3G are available, it cannot be 
excluded that mutations in those domains result in 
conformational changes that interfere indirectly with the 
protein-protein interaction, although the described 
interactions seem to be exposed in the Vif – E3 ubiquitin 
ligase complex co-crystal. 
5.4. Targeting the Vif-APOBEC3G interaction 
Mutagenesis studies and the development of peptides 
inhibiting Vif multimerization or targeting the Vif-A3G 
interaction demonstrated that targeting the Vif-A3G 
interaction could be a valuable approach 110, 119. Although Vif 
is critical for the infectivity of virus in vivo, when targeting 
the Vif-A3G interaction, some considerations need to be 
taken into account. First, an incomplete inhibition of Vif-
activity could provide viruses with a selective advantage, as 
natural Vif polymorphisms with a partially defective Vif 
show accelerated DR development 120. Secondly, the impact 
of  increasing A3G levels on cell proliferation and  tumour 
formation has to be evaluated, as A3G levels are high in 
some tumour cells 121. Third, no crystal structure of the 
complex is available which makes drug discovery quite 
challenging.  
In cellulo A3G-YFP Vif high throughput screens led to the 
discovery of 2 different classes of compounds: 1.) RN-18 
(22) or N-(2-methoxyphenyl)-2-((4-
nitrophenyl)thio)benzamide, described by Nathans et al. in 
2008 and 2.) IMB-26 (26) and IMB-35 (27) described by 
Cen et al. in 2010 17-18. More recently, VEC-5 (29) and N.41 
(30) have been discovered, using an in silico and an in vitro 
approach, respectively 19, 89 (Figure 8, table 2). 
5.4.1. RN-18 decreases Vif levels and increases 
APOBEC3G levels. 
RN-18 (22) inhibits HIV-RT activity of the X4-tropic virus 
HIV-1LAI in non-permissive A3G expressing CEM and H9 
cells with an EC50 of 4.5 µM, but not in permissive cell lines 
17. Upon adding RN-18 (22), Vif protein levels were down-
regulated, while A3G (and A3C and A3F) levels were 
upregulated, both in cells and virions. A3G incorporation 
could only be restored in a Vif-dependent manner, as a virus 
lacking Vif was not able to restore A3G levels. Likewise, 
adding RN-18 (23) neither led to increased expression of the 
A3G D128K mutant in HIV-1 producer cells. According to 
the authors, increased A3G packaging in virions, induced by 
RN-18 (23), appeared not to be due to an inhibition of the 
general proteasome- mediated pathway, as evidenced by the 
fact that p21 levels, which are modulated by the proteasome, 
were not altered. Hence, other proteins degraded by the 
proteasome could be affected. No toxicity was observed up 
till 100 µM in H9 cells. SAR optimization of RN-18 has led 
to the discovery of compounds like 5d (23) and 40 j (24) by 
Ali at al. and to the water soluble compound 17 (25) by 
Mohammed et al. 122, which could be interesting new leads 
for Vif-dependent HIV inhibitors 123. Although the results 
suggest that the effect of RN-18 (22) is Vif-dependent, no 
evidence has been shown that RN-18 (22) directly interrupts 
the interaction between Vif and A3G. 
 
5.4.2. IMB-26 and IMB-28, inhibitors of A3G degradation 
IMB-26 (26) and IMB-28 (27) were identified as specific 
inhibitors of the degradation of A3G by Vif in an in cellulo 
A3G-YFP high throughput screen 18. They bind directly to 
A3G, as studied with surface plasmon resonance (SPR) 
analysis, and abolish the Vif-A3G interaction in co-IP. They 
hamper HIV replication in non-permissive H9 cells with an 
EC50 of 17 nM. The compounds are considered as safe, with 
a therapeutic index >200 in vitro and a LD50 >1000 mg/kg 
for IMB-26(26) in BALB/c mice. Docking of these 
compounds into a A3G model based on crystal structures of 
APOBEC2 and the catalytic domain structure of A3G, 
revealed that IMB-26(26) and IMB-28 (27) likely interact 
with the A3G Y22 amino-acid through a π-π interaction, and 
with F17, W94 and A121 through hydrophobic interactions 
124. These amino-acids are predicted to mediate A3G 
oligomerization and would play a role in the interaction with 
Vif 125. 
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5.4.3. VEC-5, a Vif-ElonginC interaction inhibitor 
VEC-5 (28), a compound discovered using a virtual 
screening approach based on a Vif-EloB/C homology model, 
disrupts the interaction between Vif and EloC (a part from 
the E3 ubiquitin ligase complex), as studied by co-IP 89. 
VEC-5 (28) hampered HIV-1NL4.3 infectivity with an EC50 of 
24.48 µM (95% CI: 20.34 to 29.48 µM) when virus was 
produced in 293T cells expressing A3G. A3G and A3F 
levels in producer cells and virus particles increased upon 
addition of VEC-5 when Vif was co-expressed. Also Vif 
levels were increased upon addition of VEC-5 (28). VEC-5 
was initially predicted to bind to the Vif-binding pocket on 
EloC. Other docking studies classified it as a Vif-binder 
interfering with the Vif-A3G binding 126. Concerns for Vif-
EloC interaction blockers include a lack of specificity, as the 
BC-box for EloC binding is a conserved structure. Hence, 
the recently published crystal structure might be used as a 
base for specific drug design.   
5.4.4 N.41, a direct Vif-A3G interaction inhibitor 
Recently, a new compound, N.41 (29), was described as an 
inhibitor of the Vif-A3G interaction 19. This lead compound 
was discovered using a TR-FRET-based screen with purified 
Glutathione-S-transferase tagged Vif and the A3G110-148 
peptide and the in cellulo screen described above. N.41 
inhibited the Vif- A3G110-148 interaction for 89% when used 
at 6.25 µM. Inhibition of HIV-1Bal replication occurred at an 
IC50 of 8.4-22.6 µM in PBMCs. HIV replication was 
hampered when virus was produced on A3G expressing 
cells, but surprisingly, when produced on A3F expressing 
cells HIV replication was increased. This suggests that 
evaluating Vif-A3G inhibiting compounds as antivirals 
Figure 8, Vif-APOBEC3G inhibitors. Shown are the compounds RN-18 and analogues (22-25), IMB-26 and IMB-35 (26-
27), VEC-5 (28) and N.41 (29). 
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should include thorough testing of their effects on other A3 
family members.  
5.4. Conclusion 
In conclusion, compounds targeting the Vif-A3G interaction 
are still in an early drug discovery stage. The availability of a 
co-crystal structure would be of great help to further spur 
drug development. RN-18 (23), IMB-26 (27) and IMB-28 
(28) were mainly evaluated in cellulo, so their effect on HIV 
replication can be due to indirect down-regulation of Vif or 
up-regulation of A3G. Only the N.41 (29) compound was 
evaluated in vitro at the protein level, which suggests that 
this compound is a direct inhibitor of the Vif-A3G 
interaction. As incomplete inhibition of Vif could lead to a 
development of viruses with a selective advantage 120, 
thorough pre-clinical evaluation of Vif-A3G compounds will 
be necessary. Also the effect on other members of the A3 
family should be studied. Additionally, it is unclear if 
compounds targeting the Vif-A3G interaction will show 
sufficient antiviral activity in vivo.  
6. GENERAL DISCUSSION AND CONCLUSION 
The exponential increase of studies on virus-host interactions 
only started about a decade ago. As such it is not surprising 
that, while a lot of cellular interactions have been described, 
the way to the clinic is still long; however, significant 
progress has already been made and new cofactors are still 
discovered on a regular base. In particular, the approval of 
maraviroc in 2007 as part of antiretroviral therapy provided a 
proof-of-concept for cofactor targeting 3. In addition, a 
number of other HIV entry inhibitors made it into clinical 
trials (table 1), among them other CCR5-antagonists and 
attachment inhibitors. In particular, fostemsavir (BMS-
663068), which binds to gp-120 and prevents attachment to 
CD4, is a promising candidate for antiretroviral therapy 11. 
LEDGINs are another good example of how blue sky 
research on HIV replication can lead to the development of 
potent small molecules. First clinical trial results for 
LEDGINs were reported in 2014 7. Remaining 
pharmacokinetic problems with the BI224436 compound (9) 
with enterohepatic recirculation were solved with a scaffold 
hopping approach leading to the development of a new series 
of compounds with an improved clearance profile 81. As 
LEDGINs show additivity or synergy in combination with 
most FDA approved antiretrovirals, they could be part of 
cART. Although it is still debated whether these compounds 
mainly act through LEDGF/p75 displacement from HIV-1 
IN or IN multimerization, their discovery is intimately linked 
to the discovery of LEDGF/p75 as an IN interaction partner 
in 2003 63. Together with (co-)receptor inhibitors, LEDGINs 
prove the utility of identifying novel HIV cofactors. 
Most other inhibitors targeting cofactors or cofactor-HIV-1 
protein interactions are still in a stage of early drug 
development (table 1). This is the case for Tat-P-TEFb 
inhibitors. Targeting the Tat-P-TEFb interaction would be of 
great interest as no transactivation inhibitors of HIV-1 
replication are available yet, so these compounds would 
form a new class of antiretrovirals. Additionally, the 
observation that inhibitors of this interaction would be able 
to hamper HIV-1 production from already infected cells 
could be of great advantage as no other compounds are able 
to impede low basal HIV production from chronically 
infected cells or reactivation from latently infected cells.  
Although CDK9 was discovered as a Tat-binding partner in 
1995 (as TAK or Tat associated kinase), no compounds 
targeting CDK9 were evaluated in clinical trials during the 
last decade 5a. Lack of specificity of most kinase inhibitors 
and interference with downstream cellular processes are 
mainly responsible for this slow progress. In addition, the 
assays used to detect these compounds were based on Tat-
transactivation of a reporter gene, which could be affected by 
multiple processes. Although these issues made the 
development of Tat-P-TEFb inhibitors quite challenging, 
some progress has been made: 1.) A crystal complex of Tat 
with P-TEFb revealed conformational changes upon Tat 
binding of the ATP binding site, opening the door for 
specific CDK9 kinase inhibitors 100 2.) Recent in vivo 
validation in a humanized mice model of compounds 
targeting the Tat-CDK9 interaction is promising, although 
further optimization and evaluation is necessary 29 3.) Also 
small chemical molecules targeting the Tat-CycT1 
interaction have been described 30. Overall, with respect to 
Tat-P-TEFb inhibitors, future focus should be on the 
complex, and not on the separate proteins.  
The compounds targeting the Vif-A3G interaction are also in 
an early drug discovery stage. Despite the fact that some 
compounds which showed potent antiviral activity in vitro 
have been described, no in vivo studies have been published 
so far. So, the question remains if impairing A3G 
degradation by small chemical molecules would be sufficient 
to hamper HIV replication in in vivo conditions. Likewise, 
the effects of A3G-Vif interaction inhibitors on other A3 
family members should be systematically studied. 
Additionally, the development of inhibitors directly targeting 
Vif-A3G remains challenging as 1.) No crystal structure of 
the complex is available 2.) No protocol for purification of 
the full length proteins in large amounts is available 3.) Vif 
should be completely inhibited, as incomplete inhibition of 
Vif could lead to the production of viruses with a selective 
advantage 120. Nevertheless, inhibition of the Vif-A3G 
interaction can be seen as a boost of the innate immune 
system, which would add a new twist to antiretroviral 
therapy.  
In conclusion, the compounds discussed in this review 
demonstrate the importance of thorough validation of 
cofactors and their interaction with HIV proteins as antiviral 
targets. The obtained clinical successes validate further 
investments in HIV cofactor identification, validation and 
drug development. As only a fraction of cofactors is known 
by now, many opportunities for new antiretroviral therapies 
remain.  
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A3 or APOBEC3 Apolipoprotein B mRNA-editing 
enzyme catalytic polypeptide-like 3 
family 
AD Activation domain 
ALIX ALG-2-interacting protein X  
ATP Adenosine triphosphate 
CA Capsid 
cART Combined Anti-Retroviral Therapy 
CC50 half maximal cytotoxic concentration 
CCD Catalytic core domain 
CCR5 C-C chemokine type 5 receptor 
CD4 Cluster of differentiation 4 
CDK2 Cyclin dependent kinase 2 
CDK9 Cyclin dependent kinase 9 
cDNA Copy deoxyribonucleic acid 
Co-IP Co-immunoprecipitation 
CRM1 Chromosome region maintenance 1 
CTD C-terminal domain 
Cul5 Cullin 5 
CXCR4 C-X-C chemokine receptor type 4 
CycT1 Cyclin-T1 
CypA Cyclophylin A 
CPSF6 Cleavage and polyadenylation specific 
factor 6 
DDX3 Dead-box Helicase 3 
DR Drug resistance 
DSF Differential scanning fluorimetry 
EC50 Half maximal effective concentration 
EloB/C Elongin B/C 
ESCRT Endosomal sorting complexes required 
for transport  
FRET Förster resonance energy transfer 
Gp41 Envelope glycoprotein gp41 
Gp120 Envelope glycoprotein gp120 
HCK Tyrosine protein kinase HCK 
HDGF Hepatoma Derived Growth Factor 
HIV Human Immunodeficiency Virus 
HTRF Homogeneous Time Resolved 
Fluorescence 
IC50 Half maximal inhibitory concentration 
IN Integrase 
KD Knock-down 
KO Knock-out 
LEDGF/p75 Lens epithelium growth factor 
Nef Negative regulatory factor 
NLS Nuclear localization signal 
NTD N-terminal domain 
PIC Pre-Integration Complex 
PMA phorbol myristate acetate 
P-TEFb Positive transcription elongation factor 
SAR Structure activity relation 
SAXS Small-angle X-ray scattering 
SEC Size exclusion chromatography 
SEC-MALS SEC-multi-angle static light scattering 
SI Selectivity index 
siRNA Small interfering RNA 
SIV Simian immunodeficiency virus 
Tat Transactivator of transcription 
TAR Transactivation response element 
TNF-α Tumor necrosis factor α 
TRM Tat/TAR recognition motif 
TSG101 Tumor susceptibility gene 101 protein 
RT Reverse transcriptase 
Tat Trans-activator of transcription 
TRIM5α Tripartite motif-containing protein 5 
vDNA Viral deoxyribonucleic acid 
Vif Virus infectivity factor 
Vpr Viral protein R 
Vpu Viral protein Unique 
vDNA Viral DNA 
vRNA Viral ribonucleic acid 
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